Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
|
26332453 |
2015 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2) may be involved in the progression of prostate tumors.
|
19215786 |
2009 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2) may be involved in the progression of prostate tumors.
|
19215786 |
2009 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We sequenced 26 matched human prostate tumor and constitutional DNA samples for somatic alterations in the SRD5A2, HPRT, and HSD3B2 genes, and identified 71 nucleotide substitutions.
|
18623241 |
2009 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
|
18469342 |
2008 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
|
18268111 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
|
18306354 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
[Dutasteride in the treatment of hormone refractory prostate cancer].
|
18500220 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
|
18780294 |
2008 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
|
17376218 |
2008 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
|
17136762 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
|
17823934 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
|
17448593 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
|
17823934 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
|
17136762 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
|
16998812 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
|
16018939 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
|
15538746 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
|
16039774 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
|
15477877 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
|
15326487 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
|
12712437 |
2003 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
|
12746845 |
2003 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
|
12738739 |
2003 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
|
12771801 |
2003 |